The Best 3 Spine Specialists in Hershey, PA
Selecting a specialist in spine care requires careful evaluation. If you are looking for an experienced spine specialist in Hershey or the surrounding area, consider these top three practices.
presented by
Harmony Bio’s Zynerba Buyout Brings Cannabinoid That Doesn’t Spark Euphoria
Zynerba Pharmaceuticals’ lead drug candidate is designed to bring the therapeutic effect of cannabinoids without also causing euphoric effects. The synthetic cannabinoid in a topical gel formulation includes none of the psychoactive compounds from the cannabis plant.
presented by
The Top EAP Companies for Mental Health Support
Employee assistance programs have become essential tools for organizations aiming to address mental health challenges, reduce burnout and foster healthier workplaces.
Unions File Antitrust Complaint Against UPMC & Allege ‘Draconian’ Labor Practices
A group of labor unions have filed an antitrust complaint against UPMC. They alleged that the health system has prevented its workers from being able to advocate for themselves and their patients through “a draconian system of mobility restrictions and widespread labor law violations that lock in sub-competitive pay and working conditions.”
Mineralys IPO Lands $192M for Blood Pressure Trials and Chance to Challenge AstraZeneca
Mineralys Therapeutics upsized its IPO, raising capital to finance clinical trial plans for a molecule that could become an alternative to currently available hypertension medicines. The Mineralys molecule takes a similar approach to a drug candidate that AstraZeneca is acquiring in a $1.3 billion deal.
Debate Rages Between NPs and Docs on Whether Nurses Should Operate Independently
A contentious debate regarding whether or not nurse practitioners should have more freedom and be less tethered to doctors continues as lawmakers in Pennsylvania spark discussion.
Madrigal Drug Meets FDA’s Twin Goals for NASH, Paving Way for FDA Filing
A Madrigal Pharmaceuticals drug for the fatty liver disease NASH has data from a pivotal clinical trial showing improvements in the organ. Based on those results, which sent Madrigal's stock price soaring more than 200%, the biotech is planning to seek what could become the first regulatory approval of a therapy for this metabolic disorder.
presented by
Enhanced Direct Enrollment: Georgia Access and the Power of Partnership
Across the nation, state-based health insurance exchanges are searching for ways to better serve their communities while making enrollment easier, more personal, and more accessible for everyone.
CSL’s Gene Therapy Approval Marks First for Hemophilia B and New High in Pricing
CSL Behring's hemophilia B gene therapy, Hemgenix, carries a $3.5 million list price. But the company contends that by reducing economic burdens associated with bleeding and prophylactic infusions, the one-time treatment will save money over time.
Viatris Sees Vision Drugs as Key to Growth and Commits $750M to Two M&A Deals
Two years after the close of the merger that formed Viatris, the company is acquiring Oyster Point Pharma and Famy Life Sciences to expand its scope in ophthalmology, one of three therapeutic areas it is now focusing on for revenue growth.
Pennsylvania pharmacy owner must pay $4M for “no questions asked” oxycodone sales
A neighborhood pharmacy owner was the largest purchaser of oxycodone among retail pharmacies in the entire state of Pennsylvania by 2016 and pled guilty to charges of conspiracy and fraud.
Code Bio corrals $75M to skip viruses, use synthetic DNA for genetic meds delivery
Code Biotherapeutics uses synthetic DNA as the foundation for its genetic medicines, which the startup claims offer several key advantages compared to genetic medicines delivered via engineered viruses. The startup plans to use its new capital to develop lead programs in Duchenne muscular dystrophy and type 1 diabetes.
presented by
How (and Where) to Find the Best Value Rehabilitation Programs for Brain Injuries
Choosing the right brain injury rehabilitation program is a critical decision that can shape the future for you or your loved one.
Heart trouble report & clinical hold spell end of Antios, Assembly Bio HBV alliance
A clinical hold on an Antios Therapeutics drug has led to the end of a collaboration with Assembly Biosciences less than a year after their alliance began. The partners had hoped pairing their drugs with an approved Gilead Sciences antiviral would produce a combination hepatitis B treatment with the potential for a cure.
FDA approves Marinus Pharma drug for rare, genetic form of epilepsy
Marinus Pharmaceuticals drug Ztalmy is now FDA approved for treating the seizures in patients who have CDKL5 deficiency, an inherited form of epilepsy. The drug is the first approved treatment for the rare disorder and it’s also Marinus’s first approved product.
Biocon expands portfolio & market reach with $3.3B buyout of Viatris biosimilars
Biocon Biologics is acquiring the biosimilars business of its longtime partner, Viatris. The deal gives Biocon a biosimilars presence in both emerging and developed markets, while Viatris sheds non-core assets as part of a broader strategic review.
Transforming rural healthcare will require a funding overhaul. Here’s one way to do it.
The answer to rural healthcare's financial issues could lie in a payment model that pools funds from public and private insurers alike to pay for agreed-upon core services, allowing rural hospitals to provide the care most needed by the communities they serve.
INVEST Precision Medicine winner spotlight: Nia Therapeutics
The FDA has yet to approve a therapy for memory loss. Nia Therapeutics is developing a medical device that stimulates the brain to bring it back to a “good memory state,” and it was judged the winner in the life sciences track of the INVEST Precision Medicine Pitch Perfect Competition.